P
Paola Bernabò
Researcher at University of Genoa
Publications - 6
Citations - 1705
Paola Bernabò is an academic researcher from University of Genoa. The author has contributed to research in topics: Hypertrophic cardiomyopathy & Cardiomyopathy. The author has an hindex of 5, co-authored 6 publications receiving 1618 citations.
Papers
More filters
Journal ArticleDOI
Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.
TL;DR: In hypertrophic cardiomyopathy, the magnitude of hypertrophy is directly related to the risk of sudden death and is a strong and independent predictor of prognosis.
Journal ArticleDOI
Syncope and risk of sudden death in hypertrophic cardiomyopathy.
Paolo Spirito,Camillo Autore,Claudio Rapezzi,Paola Bernabò,Roberto Badagliacca,Martin S. Maron,Sergio Bongioanni,Fabio Coccolo,N.A. Mark Estes,Caterina S. Barillà,Elena Biagini,Giovanni Quarta,Maria Rosa Conte,Paolo Bruzzi,Barry J. Maron +14 more
TL;DR: In the present large cohort of patients with hypertrophic cardiomyopathy, unexplained syncope was a risk factor for sudden death and was maintained throughout all age groups.
Journal ArticleDOI
The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms
TL;DR: In this article, the prognostic importance of left ventricular (LV) outflow obstruction in hypertrophic cardiomyopathy (HCM) is influenced by other predictors of morbidity and mortality.
Journal ArticleDOI
Risk associated with pregnancy in hypertrophic cardiomyopathy.
Camillo Autore,Maria Rosa Conte,Marco Piccininno,Paola Bernabò,Giovanna Bonfiglio,Paolo Bruzzi,Paolo Spirito +6 more
TL;DR: Maternal mortality is increased in patients with HCM compared with the general population, however, absolute maternal mortality is low and appears to be principally confined to women at a particularly high risk.
Journal ArticleDOI
Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy.
TL;DR: The accumulated evidence strongly suggests that many patients with HC who have extreme LV hypertrophy may be candidates for potentially life-saving intervention with the implantable cardioverter-defibrillator.